Zacks Investment Research downgraded shares of Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) from a buy rating to a hold rating in a research note issued to investors on Tuesday.

According to Zacks, “Dova Pharmaceuticals, Inc. is a pharmaceutical company. It focuses on acquiring, developing and commercializing drug candidates for thrombocytopenia diseases. The company’s drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist which are in clinical stage. Dova Pharmaceuticals, Inc. is based in Durham, North Carolina. “

Several other research firms have also recently commented on DOVA. Leerink Swann started coverage on Dova Pharmaceuticals in a research report on Monday, July 24th. They issued a market perform rating and a $24.00 target price on the stock. J P Morgan Chase & Co started coverage on Dova Pharmaceuticals in a research report on Monday, July 24th. They issued an overweight rating and a $35.00 target price on the stock. Finally, Jefferies Group LLC started coverage on Dova Pharmaceuticals in a research report on Monday, July 24th. They issued a buy rating and a $30.00 target price on the stock.

Dova Pharmaceuticals (NASDAQ:DOVA) traded down $2.35 on Tuesday, reaching $22.57. The company had a trading volume of 56,400 shares, compared to its average volume of 124,678. Dova Pharmaceuticals has a 12-month low of $16.98 and a 12-month high of $29.99.

Dova Pharmaceuticals (NASDAQ:DOVA) last posted its earnings results on Thursday, November 9th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.08). During the same quarter in the previous year, the business posted ($0.41) earnings per share. equities analysts anticipate that Dova Pharmaceuticals will post -1.49 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/11/15/dova-pharmaceuticals-inc-dova-downgraded-by-zacks-investment-research-to-hold.html.

Several hedge funds have recently modified their holdings of DOVA. FMR LLC acquired a new position in shares of Dova Pharmaceuticals during the 2nd quarter valued at $43,969,000. Fosun International Ltd acquired a new position in shares of Dova Pharmaceuticals during the 2nd quarter valued at $14,489,000. Paulson & CO. Inc. acquired a new position in shares of Dova Pharmaceuticals during the 2nd quarter valued at $13,856,000. Wells Fargo & Company MN acquired a new position in shares of Dova Pharmaceuticals during the 2nd quarter valued at $4,458,000. Finally, Nexthera Capital LP acquired a new position in shares of Dova Pharmaceuticals during the 2nd quarter valued at $4,415,000. Institutional investors own 23.67% of the company’s stock.

About Dova Pharmaceuticals

Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).

Receive News & Stock Ratings for Dova Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.